A pooled analysis of advanced nonsquamous non-small cell lung cancer patients with stable treated brain metastases in two phase II trials receiving bevacizumab and pemetrexed as second-line therapy.

Fiche publication

Date publication

janvier 2018

Journal

Journal of thoracic disease

Auteurs

Membres identifiés du Cancéropôle Est :
Dr CLEMENT-DUCHENE Christelle

Tous les auteurs :
Gubens MA, Chuang JC, Akerley W, Langer CJ, Clément-Duchêne C, San Pedro-Salcedo M, Colevas AD, Dragnev K, Socinski MA, Wakelee HA

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/29600052

Résumé

Brain metastases are a common complication of advanced non-small cell lung cancer (NSCLC). Patients with brain metastases were excluded from the registration trials of bevacizumab that showed a survival benefit with the use of angiogenesis inhibition.